Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)

Telavancin is a bactericidal lipoglycopeptide antibiotic that is structurally related to vancomycin. It demonstrates in vitro activity against a variety of Gram-positive pathogens including, but not limited to, methicillin-resistant Staphylococcus aureus (MRSA). Telavancin is currently FDA-approved...

Descripción completa

Detalles Bibliográficos
Autores principales: Hooper, Candace Y, Smith, Winter J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333464/
https://www.ncbi.nlm.nih.gov/pubmed/22547931
http://dx.doi.org/10.2147/TCRM.S23247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333464/
https://www.ncbi.nlm.nih.gov/pubmed/22547931
http://dx.doi.org/10.2147/TCRM.S23247

Ejemplares similares